CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 310 enrolled
Drug / intervention
Atusin CAP +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06142994
NCT06142994N/ACompleted
CompareCT.gov

Phase 4, Efficacy and Safety of Atusin CAP in the Treatment of Subjects With Acute Bronchitis in the Primary Healthcare Setting: Prospective, Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-arm Clinical Study.

Neopharm Bulgaria Ltd.·interventional·Posted Nov 22, 2023·Updated Oct 30, 2024

In Brief

A clinical study evaluating Atusin CAP and Placebo for Acute Bronchitis. Completed, enrolled 310 participants across 1 site.

Detailed Summary

The study aims to evaluate the effectiveness and safety of Atusin® CAP in reducing the severity of acute bronchitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Bronchitis
CountriesBulgaria
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedNov 22, 2023
Enrollment StartJan 30, 2024
Primary CompletionJun 20, 2024
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.6 years ago

Interventions

Atusin CAPdietary

This food supplement contains a distillate of 4 types of purified oils - eucalyptus, sweet orange, lemon and myrtle, rich in 1,8-cineol, limonene, alpha-pinene in the ratio: 66:32:1:1, bromelain and green Brazilian propolis in a gastro-resistant capsule. The product contains excipients: microcrystalline cellulose, silica dioxide, copovidone, magnesium stearate.

Placebodietary

The placebo product will be identical in shape, appearance and color to the active product and will have the same composition but without the active ingredients.